NR4A1 and breast carcinoma: Therefore, it is apparent that the achieved rate of pathological complete response (pCR) by the use of NAC in hormone receptor-positive (HR+) breast cancer is less than ideal for both the original tumor and the axillary lymph nodes (Table 1).